CSIMarket
 


Aimmune Therapeutics Inc   (AIMT)
Other Ticker:  
 

Aimmune Therapeutics Inc 's Long Term Debt to Equity

AIMT's quarterly Long Term Debt to Equity and Long Term Debt, Equity growth


Due to net new long-term borrowings of 2.5%, Long Term Debt to Equity fell to 0.73, a new company high.

Within Major Pharmaceutical Preparations industry in the second quarter 2020, 102 other companies have achieved lower Long Term Debt to Equity than Aimmune Therapeutics Inc in the II Quarter 2020. While Long Term Debt to Equity total ranking has deteriorated compared to the first quarter 2020 from 1249 to 1958 .

Explain Long Term Debt to Equity Ratio?
How much Long Term Debt AIMT´s has?
What is the structure of AIMT´s Equity?


AIMT Long Term Debt to Equity (Jun 30 2020)
II. Quarter
(Mar 31 2020)
I. Quarter
(Dec 31 2019)
IV. Quarter
(Sep 30 2019)
III. Quarter
(Jun 30 2019)
II. Quarter
Y / Y Equity Change -12.25 % -8.29 % -65.2 % -38.22 % -28.79 %
Y / Y Long Term Debt Change 241.23 % 244.13 % - - -
Long Term Debt to Equity MRQ 0.73 0.55 0.39 0.26 0.19
AIMT's Total Ranking # 1958 # 1249 # 1174 # 1117 # 696
Seq. Equity Change -23.48 % 125.95 % -31.87 % -25.51 % -20.03 %
Seq. Long Term Debt Change 2.5 % 212.59 % 3.13 % 3.26 % 3.38 %



Long Term Debt to Equity second quarter 2020 Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry # 103
Healthcare Sector # 296
Overall Market # 1958


Long Term Debt to Equity Statistics
High Average Low
0.73 0.38 0.15
(Jun 30 2020)   (Mar 31 2019)




Financial Statements
Aimmune Therapeutics Inc 's Equity $ 180 Millions Visit AIMT's Balance sheet
Aimmune Therapeutics Inc 's Long Term Debt $ 131 Millions Visit AIMT's Balance sheet
Source of AIMT's Sales Visit AIMT's Sales by Geography


Cumulative Aimmune Therapeutics Inc 's Long Term Debt to Equity

AIMT's Long Term Debt to Equity for the trailling 12 Months

AIMT Long Term Debt to Equity

(Jun 30 2020)
II. Quarter
(Mar 31 2020)
I. Quarter
(Dec 31 2019)
IV. Quarter
(Sep 30 2019)
III. Quarter
(Jun 30 2019)
II. Quarter
Y / Y Equity TTM Growth -12.25 % -8.29 % -65.2 % -38.22 % -28.79 %
Y / Y Long Term Debt TTM Growth 241.23 % 244.13 % - - -
Long Term Debt to Equity TTM 0.51 0.36 0.22 0.13 0.08
Total Ranking TTM # 108 # 14 # 0 # 0 # 0
Seq. Equity TTM Growth -23.48 % 125.95 % -31.87 % -25.51 % -20.03 %
Seq. Long Term Debt TTM Growth 2.5 % 212.59 % 3.13 % 3.26 % 3.38 %


On the trailing twelve months basis Due to the net new long-term borrowings of 2.5% during the trailing twelve months finishing in the II Quarter 2020, cumulativeLong Term Debt to Equity improved to 0.51, a new company high.
Long Term Debt to Equity is the average cumulative value over the last four quarters.

Among companies in the Major Pharmaceutical Preparations industry 20, during the past 12 months, other companies have achieved lower Long Term Debt to Equity than Aimmune Therapeutics Inc . While Long Term Debt to Equity total ranking has deteriorated during the twelve months ending in the II Quarter 2020, compared to the prior period, from 14 to 108.

Explain Long Term Debt to Equity Ratio?
How much Long Term Debt AIMT´s has?
What is the structure of AIMT´s Equity?

TTM Long Term Debt to Equity Company Ranking
Within: No.
Within the Major Pharmaceutical Preparations Industry # 21
Healthcare Sector # 32
Within the Market # 108


trailing twelve months Long Term Debt to Equity Statistics
High Average Low
0.51 0.22 0.03
(Jun 30 2020)   (Mar 31 2019)




Companies with similar Long Term Debt to Equity in the quarter ending Jun 30 2020, within Major Pharmaceutical Preparations Industry Long Term Debt to EquityJun 30 2020 MRQ Long Term DebtJun 30 2020 MRQ Equity
Lannett Company Inc  1.96 $ 592.940  Millions$ 302.896  Millions
Phibro Animal Health Corporation  1.96 $ 368.257  Millions$ 188.204  Millions
Evolus Inc   1.70 $ 74.165  Millions$ 43.603  Millions
Teva Pharmaceutical Industries Limited  1.66 $ 24,616.000  Millions$ 14,824.000  Millions
Apellis Pharmaceuticals Inc   1.50 $ 348.842  Millions$ 232.064  Millions
Collegium Pharmaceutical Inc   1.48 $ 229.908  Millions$ 155.767  Millions
Organogenesis Holdings Inc   1.46 $ 52.364  Millions$ 35.750  Millions
Prestige Consumer Healthcare Inc   1.32 $ 1,620.641  Millions$ 1,227.014  Millions
Rockwell Medical inc   1.28 $ 20.764  Millions$ 16.212  Millions
Amag Pharmaceuticals inc   1.14 $ 285.137  Millions$ 249.322  Millions
Assertio Holdings inc   1.08 $ 91.834  Millions$ 84.978  Millions
Catalent Inc   1.02 $ 2,945.100  Millions$ 2,898.800  Millions
Merck and Co Inc   0.94 $ 26,156.000  Millions$ 27,744.000  Millions
Ani Pharmaceuticals Inc  0.93 $ 177.879  Millions$ 191.344  Millions
Biodelivery Sciences International Inc   0.92 $ 78.274  Millions$ 84.770  Millions
Karyopharm Therapeutics Inc   0.88 $ 113.776  Millions$ 129.799  Millions
Cryoport inc   0.88 $ 110.977  Millions$ 126.657  Millions
Insmed Inc  0.85 $ 346.001  Millions$ 405.318  Millions
Bristol myers Squibb Company  0.85 $ 41,853.000  Millions$ 49,160.000  Millions
Liquidia Corporation  0.85 $ 7.505  Millions$ 8.870  Millions
Eterna Therapeutics Inc   0.84 $ 1.625  Millions$ 1.931  Millions
Pacira Biosciences inc   0.81 $ 314.182  Millions$ 388.148  Millions
Tricida Inc   0.79 $ 182.597  Millions$ 230.980  Millions
Pfizer Inc  0.78 $ 50,529.000  Millions$ 64,564.000  Millions
Innoviva Inc   0.77 $ 381.230  Millions$ 492.812  Millions
Mylan N v   0.77 $ 8,994.400  Millions$ 11,746.200  Millions
Athenex Inc   0.76 $ 95.389  Millions$ 126.246  Millions
Otonomy Inc   0.74 $ 15.069  Millions$ 20.249  Millions
Aimmune Therapeutics Inc   0.73 $ 131.462  Millions$ 179.858  Millions
Avadel Pharmaceuticals Plc  0.69 $ 124.879  Millions$ 182.125  Millions

Date modified: 2023-03-24T07:53:52+00:00



Help

About us

Advertise

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2024 CSIMarket, Inc. All rights reserved. This site uses cookies to make your browsing experince better. By using this site, you agree to the Terms of Service and Privacy Policy - UPDATED (Read about our Privacy Policy)

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com